Potential challenge for second-line treatments of unresectable locally or advanced-stage non-small-cell lung carcinoma unharbored sensitive driver gene mutation: A pilot study of novel antiangiogenesis inhibitor (NCT: 0325672121).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21197-e21197
Author(s):  
Zongyang Yu ◽  
Jinhuo Lai ◽  
Zhiyong He ◽  
Zhengwu Xu ◽  
Xi Shi ◽  
...  
Keyword(s):  
Pilot Study ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Driver Gene ◽  
Advanced Stage ◽  
Second Line ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Potential Challenge

Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients

Lung Cancer ◽  
2008 ◽  
Vol 61 (2) ◽  
pp. 170-176 ◽  
Author(s):  
Paal Fr Brunsvig ◽  
Kjersti Flatmark ◽  
Steinar Aamdal ◽  
Hanne Høifødt ◽  
Hang Le ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Bone Marrow Micrometastases

scholarly journals A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma

2021 ◽  
pp. LMT47
Author(s):  
Jerónimo Rafael Rodríguez-Cid ◽  
Sonia Carrasco-Cara Chards ◽  
Iván Romarico González-Espinoza ◽  
Vanessa García-Montes ◽  
Julio César Garibay-Díaz ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Objective Response ◽  
Small Cell ◽  
Immune Checkpoints ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
Total Study Population ◽  
Cell Lung Carcinoma

Background: Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy.  Materials and methods: This was a retrospective review among eight medical centers comprising 100 patients with a confirmed diagnosis of non-small-cell lung carcinoma, in their second-line treatment or beyond with immune checkpoints inhibitors treatment. The current study aimed to analyze effectiveness of immunotherapy in second-line treatment or further in the Mexican population, using PFS rate, OS rate and the best objective response to treatment by RECIST 1.1 as a surrogate of effectiveness. Results: In total, 100 patients met the criteria for enrollment in the current study. From the total study population, 49 patients (49.0%) were male and 51 (51.0%) were female, with an average age of 60 years and stage IV as the most prevalent clinical stage at the beginning of the study. A total of 61 patients (61.0%) had partial response; 11 (11.0%) stable disease; 2 (2.0%), complete response, 4 (4.0%), progression; and 22 (22.0%) were nonevaluable. We found a median PFS of 4 months (95% CI: 3.2–4.7 months) and an OS of 9 months (95% CI: 7.2–10.7 months). Conclusion: The response to immunotherapy is similar, with an improvement in OS and PFS, independent of which drug is used. Patients using nivolumab had a better survival, although that was not statistically significant.

Relationship between driver gene mutations, their relative protein expressions and survival in non‐small cell lung carcinoma in Macao

2017 ◽  
Vol 12 (4) ◽  
pp. 1416-1423
Author(s):  
Kin Iong Chan ◽  
Hong Ting Vong ◽  
Lai Fong Sin ◽  
Yuk Ching Yip ◽  
Xue Yun Zhong ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Gene Mutations ◽  
Small Cell ◽  
Driver Gene ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Protein Expressions

AN AUDIT OF LUNG CARCINOMAS AT A TERTIARY REFERRAL CENTRE

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Anshita Dubey ◽  
Meenal Hastak ◽  
Bijal Kulkarni ◽  
Nevitha Athikari ◽  
Rajesh Mistry
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Generic Diagnosis ◽  
Advanced Stage ◽  
Histological Subtype ◽  
Small Cell Lung ◽  
Significant Treatment ◽  
Cell Lung Carcinoma ◽  
Lung Carcinomas

A generic diagnosis of ‘small cell or non-small cell carcinoma’ was sufficient in the past when there was no clinical demand for sub classification as it had no impact on therapy. Patients with advanced stage non-small cell lung carcinoma who received chemotherapy were typically treated with a ‘platinum doublet’ of cisplatin plus gemcitabine irrespective of histological subtype. At present, in contrast, sub classification of non-small cell lung carcinoma has significant treatment implications, especially for advanced stage tumors for which chemotherapy or targeted therapy is being considered. Consequently, pathologists are asked to subtype the tumor. The demand for sub typing is driven by oncologists, who now have several new targeted therapies, the efficacy of which varies by histological subtype. In view of demand of sub typing of lung carcinomas as well as the guidelines given by WHO 2015 classification which emphasises the importance of a separate classification for biopsies and cytology on one side and the resection specimen on the other, we have taken up this study. Keywords: Lung carcinoma, classification, core biopsies, immunohistochemistry

Pilot Study with Cisplatin, Ifosfamide, and Etoposide in Advanced Non-Small-Cell Lung Carcinoma

1990 ◽  
Vol 13 (5) ◽  
pp. 424-426 ◽  
Author(s):  
Paolo Bidoli ◽  
Silvia Spinazze ◽  
Armando Santoro ◽  
Paolo Casali ◽  
Amedeo Vittorio Bedini ◽  
...  
Keyword(s):  
Pilot Study ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma
Sign in / Sign up

Export Citation Format

Share Document